{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-25-000003","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2025-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.876841+00:00","generated_at":"2026-05-28T02:10:40.310941+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ImmuneOnco doses first patient in Instil's IMM2510 Phase 1b/2 NSCLC trial; data in 2H 2025","bullets":["ImmuneOnco dosed first patient in combined-chemotherapy trial for advanced NSCLC in China.","Initial clinical data for 1L advanced NSCLC expected as early as second half of 2025.","Instil targets initiating U.S. first-line NSCLC trial of IMM2510 plus chemo in 2H 2025, subject to regulatory approvals.","CEO Bronson Crouch says positive data could enable a global registrational study in front-line NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-25-000003","json":"https://secwatch.observer/filing/0001789769-25-000003.json","markdown":"https://secwatch.observer/filing/0001789769-25-000003.md","text":"https://secwatch.observer/filing/0001789769-25-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976925000003/0001789769-25-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976925000003/til-20250114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:10:40.310941+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}